Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 14/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 10/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 10/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 10/20 | 0.47 |
| ▸ | PRKAG3 | Q9UGI9 | 10/20 | 0.47 |
| ▸ | PRKAG2 | Q9UGJ0 | 10/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 10/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62208 | 0.94 | MAPT (0.57) | MAPTPRKAA2PRKAB2PRKAG1PRKAA1 | |
| Trifluoroacetic Acid SCHEMBL63390 | 0.90 | MAPT (0.54) | MAPTPRKAA2PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL62186 | 0.89 | MAPT (0.54) | MAPTPRKAA2PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL61866 | 0.87 | PRKAA2 (0.51) | MAPTPRKAA2PRKAB2PRKAG1PRKAA1 | |
| Trifluoroacetic Acid SCHEMBL63294 | 0.84 | PRKAA2 (0.48) | MAPTPRKAA2PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL61592 | 0.83 | HDAC1 (0.49) | MAPTPRKAA2PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL60899 | 0.81 | AKR1B1 (0.56) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL61772 | 0.81 | HDAC1 (0.61) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL61254 | 0.81 | HDAC1 (0.52) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL61682 | 0.80 | DRD4 (0.53) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129390-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | MAPT 2174/4885PRKAA2 3/4885PRKAB2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.